Adamas Pharmaceuticals Inc (NASDAQ:ADMS) was the target of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 7,125,630 shares, a decline of 11.3% from the November 15th total of 8,033,382 shares. Based on an average daily volume of 1,097,522 shares, the days-to-cover ratio is presently 6.5 days. Approximately 41.0% of the shares of the company are short sold.
Shares of Adamas Pharmaceuticals (NASDAQ ADMS) traded up $0.50 during mid-day trading on Monday, reaching $32.58. The company’s stock had a trading volume of 3,090,800 shares, compared to its average volume of 548,807. The company has a quick ratio of 8.32, a current ratio of 8.35 and a debt-to-equity ratio of 0.41. Adamas Pharmaceuticals has a one year low of $13.50 and a one year high of $38.22.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.01) by ($0.03). The business’s revenue for the quarter was down 99.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.66) earnings per share. equities analysts expect that Adamas Pharmaceuticals will post -3.84 EPS for the current year.
ADMS has been the subject of a number of analyst reports. ValuEngine upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Piper Jaffray Companies reiterated an “overweight” rating and set a $30.00 price target on shares of Adamas Pharmaceuticals in a research report on Wednesday, September 20th. Mizuho reiterated a “buy” rating and set a $48.00 price target (up previously from $26.00) on shares of Adamas Pharmaceuticals in a research report on Wednesday, September 13th. William Blair reiterated an “ourperform” rating on shares of Adamas Pharmaceuticals in a research report on Friday, August 25th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $38.00 price target on shares of Adamas Pharmaceuticals in a research report on Sunday, September 17th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $42.00.
ILLEGAL ACTIVITY WARNING: “Adamas Pharmaceuticals Inc (ADMS) Short Interest Down 11.3% in November” was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/12/18/adamas-pharmaceuticals-inc-adms-short-interest-down-11-3-in-november.html.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.